TCG Advisors’s Accelerate Diagnostics AXDX Stock Holding History

TCG Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20	Closed	-$5K	–	134
2019 Q2	$5K	Buy	+20	New	+$3.91K	﹤0.01%	308

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

TCG Advisors's AXDX Position: Q3 2019 in Review

TCG Advisors sold out of Accelerate Diagnostics (AXDX) in Q3 2019, closing a stake of 20 shares — an estimated $5K sold.

TCG Advisors first reported a position in AXDX in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 113 funds tracked by Wall St. Rank hold AXDX as of Q3 2019.

TCG Advisors reported no remaining Accelerate Diagnostics position as of Q3 2019 after selling out during the quarter.
TCG Advisors sold 20 Accelerate Diagnostics shares in Q3 2019, an estimated $5K.
TCG Advisors first reported a position in Accelerate Diagnostics in Q2 2019 and held it in 1 quarter.
TCG Advisors's Accelerate Diagnostics position peaked at $5K in Q2 2019.
113 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2019.

Based on TCG Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.